downgrad bari adcom
adjust ep exclud non-cash one-tim item
headquart wilmington de biotechnolog compani develop drug treat cancer
autoimmun diseas epacadostat ido inhibitor test combin multipl tumor type
april merck announc phiii epacadostat keytruda vs keytruda
monotherapi melanoma meet primari endpoint progression-fre surviv overal surviv
surpris fail patient studi epa keytruda vs keytruda show hazard ratio
hr confid interv ci hr os ci result
came surpris given combo superior month phi/ii manag state
keytruda arm perform similarli previou trial month group patient
posit believ differ attribut small patient popul phi/ii
happen easier treat express meanwhil monotherapi efficaci
bar set high combo slight posit player
write epa tumor type statu random arm like pd-
posit vs neg arm believ combo would perform significantli better
posit cutoff group biomark includ ido tumor mutat burden tmb statu
analyz expect substanti impact therefor remov epa
indic valuat biomark data disclos later year also remov
expens estim epa launch sg addit expens associ epa start
valu jakafi bari adcom remain posit jakafi long-term growth maintain peak sale
estim valu jakafi ex-u royalti per share upcom catalyst
fda advisori committe adcom baricitinib apr estim possibl success
per share valu inci royalti drug expect downsid
adcom give neg opinion usual lead reject
downgrad bari risk believ still attract takeout target novarti sell jakafi
ex-u could appreci valu meanwhil celgen may also interest synergi
jakafi fedratinib jak inhibitor acquir januari second-lin use patient intoler
jakafi total patient popul downgrad hold despit discount
pmv estim per share recommend stay sidelin baricitinib adcom
exclud non-cash one-tim item beyond
fiscal year end million except per share cont op tev/ebitda multipl
jing research analyst prepar report herebi certifi view express report accur reflect analyst
person view subject compani secur research analyst receiv direct
indirect compens express specif recommend view report
